SHBG and adrenal cortex carcinoma: Early studies demonstrated that most ACC patients treated with mitotane have increased levels of sex hormone-binding globulin (SHBG), a glycoprotein involved in binding and transport of circulating plasma testosterone and 17β-estradiol (E2) to target tissues [9,14].